Skip to main content

Side-by-side guide

Compare peptides and GLP-1 medications

Choose a pair to compare approval, dose, results and side effects. Only 3 of the 12 pairs have been tested directly against each other. For the other 9, we keep each drug’s results separate instead of pretending two different studies are a head-to-head trial.

What matters first

Total comparisons
12
With a direct trial
3
Without a direct trial
9
Tirzepatide vs semaglutideHead-to-head trial

SURMOUNT-5: 751 adults over 72 weeks. Each person moved up to the highest dose they could handle.

FDA labelFDA label

Wegovy vs ZepboundProduct comparisonHead-to-head trial

Two FDA-approved products built on these ingredients: the conditions FDA cleared for each product, the people covered, both label titration schedules, and the devices.

Retatrutide vs tirzepatide

No head-to-head trial exists. Each record is reported on its own terms, with its own citation.

Human trialFDA label

Survodutide vs tirzepatide

No head-to-head trial exists. Each record is reported on its own terms, with its own citation.

Human trialFDA label

Tesamorelin vs sermorelin

Two drugs at the same pituitary receptor. One is still approved. The other’s approval was withdrawn in 2009, which is why it is compounded today.

FDA labellimited human data

Tesamorelin vs CJC-1295

An approved daily injection against a research peptide sold in two forms under one name. One lasts days. The other lasts minutes.

FDA labellimited human data

Mounjaro vs OzempicProduct comparisonHead-to-head trial

SURPASS-2: 1,879 adults over 40 weeks, plus 9 rows read from both FDA labels.

Wegovy vs OzempicProduct comparison

Wegovy and Ozempic are the same drug substance. 4 of 11 label rows come back identical and 7 do not.

Mounjaro vs ZepboundProduct comparison

Mounjaro and Zepbound are the same drug substance. 7 of 11 label rows come back identical and 4 do not.

Zepbound vs OzempicProduct comparison

Two different drugs, 13 rows read from both FDA labels, and no trial that compared this pair.

Wegovy vs MounjaroProduct comparison

Two different drugs, 14 rows read from both FDA labels, and no trial that compared this pair.

GLP-1 pill vs injectionForm comparison

The same molecule in a daily tablet and a weekly shot, across 3 tablet products and two FDA labels. No trial compares the two forms, and the labels’ own switching instructions are the closest thing to an official swap.

What makes a fair comparison?

A direct trial is the strongest way to compare two treatments because the same study tests both. When no direct trial exists, we show each treatment’s evidence in separate columns and label that limit clearly.

Product comparisons use the current FDA labels. Form comparisons focus on practical differences between versions of the same medicine, such as a tablet and an injection.

Using two at once is a separate question, and none of these pages answers it. The combination records cover what happens when someone stacks two, including the searches that show which pairs nobody has ever tested together.

A comparison page holds no clinical values of its own. Every row on one is read at render time from the pages, tools and gradings below.

The peptide calculator behind every compound here

One tool, 36 pages: vial strength, water volume and dose to an exact draw.

The other reactions read the same way

One row of a profile, taken down every page in the database.

Swallowing it or injecting it, row by row

One drug substance in two forms, so every row that separates two molecules is identical here.

Where each compound stands with the regulator

Approval status, review proceedings and the dates attached to each.

The full page index behind these pages

The spine every dosing, safety and calculator page reads from.

How strong is each kind of source?

The difference between an approved label, a human study and a compound with no human data.